Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab before surgery in SCCHN
NCT02827838Phase 1Terminated
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jan 2017
- Primary completion
- Apr 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Wake Forest University Health Sciences. Primary endpoints: Immune Effector Assessed in Blood by Flow Cytometry and in Tissue by Immunohistochemistry at 18 months, Immune-regulatory miR Responses as Measured in Plasma Assessed by Quantitative Reverse Transcriptase PCR at 1 week and 5 more. Started Jan 2017; status: terminated.
02
Drugs
durvalumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02827838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02827838.